Long-Term Percutaneous Coronary Intervention Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial)

Drug-eluting stents (DESs) use a polymer to fix and modulate the elution of cytotoxic drugs, with the aim of preventing in-stent restenosis. The persistence of the polymer after drug elution can result in delayed arterial healing and subsequently late stent thrombosis and in-stent restenosis.1,2 This led to the development of biocompatible durable and biodegradable polymers. The latter gradually loses its polymer after drug elution to leave a bare-metal stent in situ and is the fundamental premise for developing biodegradable polymer (BP) DESs.

Source: The American Journal of Cardiology - February 11, 2024 Category: Cardiology Authors: Kush P. Patel, Alexandra J. Lansky, Henning Kelb æk, Bo Xu, Niels van Royen, Thomas W. Johnson, Richard Anderson, William Wijns, Andreas Baumbach, TARGET AC investigators Source Type: research